Caroline A. Lee

TL;DR: Overall, it is advised that the timing of transporter investigations should be driven by efficacy, safety and clinical trial enrolment questions, as well as a need for further understanding of the absorption, distribution, metabolism and excretion properties of the drug molecule, and information required for drug labelling.

TL;DR: This study was conducted to determine whether the pharmacokinetic differences between Japanese and white subjects extended to other Asian ethnic groups and whether polymorphisms in the SLCO1B1 gene contribute to any pharmacokinetics differences observed.

TL;DR: The clinical pharmacokinetics and in vitro inhibition of digoxin were examined to predict the P‐glycoprotein (P‐gp) component of drug–drug interactions and found that digoxin is likely to show the highest perturbation, via inhibition of P‐gp, because of the absence of metabolic clearance.

TL;DR: A new cell line, MDCKII-LE (low efflux), has been developed by selecting a subpopulation of low-efflux cells from MDCkII-WT using an iterative fluorescence-activated cell sorting technique with calcein-AM as a Pgp and efflux substrate.

TL;DR: This white paper provides a critical analysis of methods for estimating transporter kinetics and recommendations on proper parameter calculation in various experimental systems and appropriate guidance for the use of in vitro, in vivo, and modeling tools in translational transporter science.